BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$0.061|
|52 Week High||NZ$0.054|
|52 Week Low||NZ$0.086|
|1 Month Change||-7.58%|
|3 Month Change||-15.28%|
|1 Year Change||-29.07%|
|3 Year Change||258.82%|
|5 Year Change||22.00%|
|Change since IPO||-93.84%|
Recent News & Updates
Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)
How far off is BLIS Technologies Limited ( NZSE:BLT ) from its intrinsic value? Using the most recent financial data...
BLIS Technologies Limited (NZSE:BLT) Insiders Have Been Selling
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
BLIS Technologies (NZSE:BLT) has had a rough three months with its share price down 8.1%. But if you pay close...
I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|BLT||NZ Pharmaceuticals||NZ Market|
Return vs Industry: BLT underperformed the NZ Pharmaceuticals industry which returned 0.4% over the past year.
Return vs Market: BLT underperformed the NZ Market which returned 1.9% over the past year.
Stable Share Price: BLT is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BLT's weekly volatility (5%) has been stable over the past year.
About the Company
BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of infants and children, as well as for improving bad breath; and BLIS M18 for promoting the bacterial balance for dental health. Its product portfolio consists of DailyDefence, a daily probiotic to support throat immunity; DailyDefence Junior, a daily powder formulation to support ear, nose, and throat health of infants and small children; ThroatGuard PRO to give immunity support to help protect against winter ills; ElitePRO, a suite of WADA tested products for athletes; and TravelProtect to help support the immune system when travelling.
BLIS Technologies Fundamentals Summary
|BLT fundamental statistics|
Is BLT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLT income statement (TTM)|
|Cost of Revenue||NZ$1.88m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.00044|
|Net Profit Margin||5.21%|
How did BLT perform over the long term?See historical performance and comparison
Is BLIS Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLT is poor value based on its PE Ratio (138.6x) compared to the Oceanic Pharmaceuticals industry average (44.9x).
PE vs Market: BLT is poor value based on its PE Ratio (138.6x) compared to the NZ market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLT is overvalued based on its PB Ratio (13.7x) compared to the XO Pharmaceuticals industry average (3.5x).
How is BLIS Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIS Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has BLIS Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLT has a high level of non-cash earnings.
Growing Profit Margin: BLT's current net profit margins (5.2%) are lower than last year (14.8%).
Past Earnings Growth Analysis
Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by 58.8% per year.
Accelerating Growth: BLT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLT had negative earnings growth (-64.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.4%).
Return on Equity
High ROE: BLT's Return on Equity (10%) is considered low.
How is BLIS Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: BLT's short term assets (NZ$5.1M) exceed its short term liabilities (NZ$1.8M).
Long Term Liabilities: BLT's short term assets (NZ$5.1M) exceed its long term liabilities (NZ$332.0K).
Debt to Equity History and Analysis
Debt Level: BLT's debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BLT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BLT's debt is well covered by operating cash flow (709.6%).
Interest Coverage: BLT's interest payments on its debt are well covered by EBIT (142x coverage).
What is BLIS Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Brian D. Watson, B Com (Marketing), B Ph Ed, has been Chief Executive Officer of BLIS Technologies Limited since February 15, 2016. Mr. Watson has strong sales and marketing credentials and expertise....
Experienced Management: BLT's management team is seasoned and experienced (5.1 years average tenure).
Experienced Board: BLT's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.
BLIS Technologies Limited's employee growth, exchange listings and data sources
- Name: BLIS Technologies Limited
- Ticker: BLT
- Exchange: NZSE
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$77.702m
- Shares outstanding: 1.27b
- Website: https://www.blis.co.nz
Number of Employees
- BLIS Technologies Limited
- 81 Glasgow Street
- South Dunedin
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 15:39|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.